Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

ive pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

M6G's lower propensity to cause nausea and vomiting in the post-operative period strongly supports CeNeS' belief in the potential of M6G as a novel product for the treatment of post-operative pain with clear advantages over morphine.

3. Safety profile/adverse events

The trial confirmed that M6G's safety profile is similar to morphine. Aside from nausea and vomiting, the adverse events reported were at levels similar to those experienced by patients receiving morphine in a post-operative setting.

M6G022 Study Design The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the "gold standard" drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatment was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- Treatment with either M6G or morphine, particularly during PCA, results in similar levels of pain management; and

- Effective analgesic treatment during PCA results i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
(Date:12/22/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... of chronic pain, announced today that the first ... pharmacokinetic and pharmacodynamic study with d-Methadone, the company,s ... Racemic methadone is a long-acting opioid used ... substitution therapy in opioid addiction.  It is constituted ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
(Date:12/24/2014)... By Tara Haelle ... (HealthDay News) -- Teens are more likely to start ... of attention-deficit hyperactivity disorder (ADHD) or conduct disorder, ... to counsel families about the risk of substance use ... William Brinkman, research director at Cincinnati Pediatric Research Group, ...
(Date:12/24/2014)... Angeles, CA (PRWEB) December 24, 2014 ... wreak havoc on those who have an intolerance to ... to diarrhea, gas, bloating, migraine headaches, joint pain and ... gluten free diet plans that deliver safe and ... certain foods that trigger a gluten allergy reaction. These ...
(Date:12/24/2014)... MA (PRWEB) December 24, 2014 Dr. ... Dentists from across the nation gathered with US Marines ... Dinner to raise funds for the Toys for Tots ... hundreds of thousands of new books and audio books ... go to underprivileged children this Christmas. It represents another ...
(Date:12/24/2014)... There’s a lot going on with The ... now in control of the Senate as well as the ... Act. A lawsuit has been brought against President Obama by ... the ACA have resulted in changes to the law without ... will take place to weigh the validity of subsidies provided ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 2Health News:Diet Doc Adds Gluten Free Diet Plans to Their Stable of Specialized Weight Loss Programs 3Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3
... breathing disorders could face depression, says a study.// ... Wisconsin-Madison studied about 1,400 adults (aged 30-60) for up ... did not have breathing problems during sleep, those with ... times more likely to become depressed during the study, ...
... Anna Pou, during her first ever public appearance, since ... with dangerous injections, confirmed that neither she nor// the ... ,The charge labeled against them by the Louisiana ... second-degree murder. The witness account as mentioned in ...
... has revealed that exposure to high pollution levels can increase ... in Japan have found that the risk of stroke from ... ,Currently breathing and heart problems are associated with the ... hourly levels. ,The findings of the study ...
... (FDA) have approved a virus mix in spray form that ... month.// , ,Processed meats after being packaged get ... combination of viruses that kill this bacteria. Food companies can ... ,This virus mix is not effective against E. ...
... poor training is resulting in unnecessary emergency Caesarean births ... week’s British Medical Journal (BMJ) that expert obstetricians can ... UK, the decision whether to try a vaginal birth, ... Caesarean is taken in the delayed second-stage labor by ...
... A House committee on Wednesday passed a bill that will ... from the South and rural states said that// increased spending ... it is spreading. ,"It shouldn't matter where you ... care and therapy," said Rep. Joe Barton, R-Texas, chairman of ...
Cached Medicine News:Health News:Stroke Linked to High Pollution Levels 2Health News:Skilled Obstetricians to avoid unnecessary Caesareans 2
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Medicine Products: